Industry's opinion on 'New Use'

WASHINGTON - Based on comments submitted in response to the FDA's "New Use Initiative" guidances covering clinical evidence of efficacy and the new application of existing cancer therapies, biotechnology and pharmaceutical industry representatives are underwhelmed by the agency's proposals.

"While PhRMA member companies applaud FDA's apparent willingness to move toward

Read the full 499 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE